Dominguez J

References (6)

Title : Exploring the potential enzymatic bioremediation of vermicompost through pesticide-detoxifying carboxylesterases - Sanchez-Hernandez_2019_Ecotoxicol.Environ.Saf_183_109586
Author(s) : Sanchez-Hernandez JC , Cares XA , Dominguez J
Ref : Ecotoxicology & Environmental Safety , 183 :109586 , 2019
Abstract : Vermicompost is a known biofertilizer of potential use in soil bioremediation. This study was undertaken to explore the capacity of grape marc-derived vermicompost to inactivate methyl carbamate (MC) and organophosphorus (OP) pesticides via exploring the carboxylesterase (CE) activity level and its response to pesticide exposure. We first optimized the method for enzyme activity assay comparing the CE activity in two contrasting homogenization procedures (30-min mixing and mortar grinding). Thereafter, we assessed the sensitivity of the enzyme by both in vitro and vermicompost incubation trials with selected pesticides. The main findings can be summarized as follows: i) grinding the vermicompost in water (2% w/v) yielded maximum enzyme activity; ii) at concentrations around 10(-4)M, highly toxic oxygen-analog metabolites of OPs strongly inhibited the CE activity (76-93% inhibition), but MC did not inhibit the enzyme activity; iii) liquid vermicompost was able to degrade chlorpyrifos and inactivate its highly toxic metabolite chlorpyrifos-oxon. Our results suggest that liquid vermicompost is the most appropriate preparation to increase the enzymatic potential of vermicompost in pesticide-contaminated soils.
ESTHER : Sanchez-Hernandez_2019_Ecotoxicol.Environ.Saf_183_109586
PubMedSearch : Sanchez-Hernandez_2019_Ecotoxicol.Environ.Saf_183_109586
PubMedID: 31450034

Title : Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761((R)) - Kandiah_2019_CNS.Neurosci.Ther_25_288
Author(s) : Kandiah N , Ong PA , Yuda T , Ng LL , Mamun K , Merchant RA , Chen C , Dominguez J , Marasigan S , Ampil E , Nguyen VT , Yusoff S , Chan YF , Yong FM , Krairit O , Suthisisang C , Senanarong V , Ji Y , Thukral R , Ihl R
Ref : CNS Neurosci Ther , 25 :288 , 2019
Abstract : BACKGROUND: The Ginkgo biloba special extract, EGb 761((R)) has been widely used in the treatment of neuropsychiatric disorders, including Alzheimer's disease (AD). METHODS: To guide clinical practice in the Asian region, the Asian Clinical Expert Group on Neurocognitive Disorders compiled evidence-based consensus recommendations regarding the use of EGb 761((R)) in neurocognitive disorders with/without cerebrovascular disease. RESULTS: Key randomized trials and robust meta-analyses have demonstrated significant improvement in cognitive function, neuropsychiatric symptoms, activities of daily living (ADL) and quality of life with EGb 761((R)) versus placebo in patients with mild-to-moderate dementia. In those with mild cognitive impairment (MCI), EGb 761((R)) has also demonstrated significant symptomatic improvement versus placebo. World Federation of Societies of Biological Psychiatry guidelines list EGb 761((R)) with the same strength of evidence as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) antagonists e.g. memantine (Grade 3 recommendation; Level B evidence). Only EGb 761((R)) had Level B evidence in improving cognition, behaviour, and ADL in both AD and vascular dementia patients. Safety analyses show EGb 761((R)) to have a positive risk-benefit profile. While concerns have been raised regarding a possible increased bleeding risk, several randomized trials and two meta-analyses have not supported this association. CONCLUSIONS: The Expert Group foresee an important role for EGb 761((R)) , used alone or as an add-on therapy, in the treatment of MCI and dementias, particularly when patients do not derive benefit from acetylcholinesterase inhibitors or NMDA antagonists. EGb 761((R)) should be used in alignment with local clinical practice guidelines.
ESTHER : Kandiah_2019_CNS.Neurosci.Ther_25_288
PubMedSearch : Kandiah_2019_CNS.Neurosci.Ther_25_288
PubMedID: 30648358

Title : Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region - Chen_2016_J.Intern.Med_280_359
Author(s) : Chen C , Homma A , Mok VC , Krishnamoorthy E , Alladi S , Meguro K , Abe K , Dominguez J , Marasigan S , Kandiah N , Kim SY , Lee DY , De Silva HA , Yang YH , Pai MC , Senanarong V , Dash A
Ref : J Intern Med , 280 :359 , 2016
Abstract : BACKGROUND: There is growing awareness of the coexistence of Alzheimer's disease and cerebrovascular disease (AD+CVD), however, due to lack of well-defined criteria and treatment guidelines AD+CVD may be underdiagnosed in Asia.
METHODS: Sixteen dementia specialists from nine Asia Pacific countries completed a survey in September 2014 and met in November 2014 to review the epidemiology, diagnosis and treatment of AD+CVD in Asia. A consensus was reached by discussion, with evidence provided by published studies when available.
RESULTS: AD accounts for up to 60% and AD+CVD accounts for 10-20% of all dementia cases in Asia. The reasons for underdiagnosis of AD+CVD include lack of awareness as a result of a lack of diagnostic criteria, misdiagnosis as vascular dementia or AD, lack of diagnostic facilities, resource constraints and cost of investigations. There is variability in the tools used to diagnose AD+CVD in clinical practice. Diagnosis of AD+CVD should be performed in a stepwise manner of clinical evaluation followed by neuroimaging. Dementia patients should be assessed for cognition, behavioural and psychological symptoms, functional staging and instrumental activities of daily living. Neuroimaging should be performed using computed tomography or magnetic resonance imaging. The treatment goals are to stabilize or slow progression as well as to reduce behavioural and psychological symptoms, improve quality of life and reduce disease burden. First-line therapy is usually an acetylcholinesterase inhibitor such as donepezil. CONCLUSION: AD+CVD is likely to be under-recognised in Asia. Further research is needed to establish the true prevalence of this treatable and potentially preventable disease.
ESTHER : Chen_2016_J.Intern.Med_280_359
PubMedSearch : Chen_2016_J.Intern.Med_280_359
PubMedID: 26992016

Title : Earthworm-induced carboxylesterase activity in soil: Assessing the potential for detoxification and monitoring organophosphorus pesticides - Sanchez-Hernandez_2015_Ecotoxicol.Environ.Saf_122_EES15582
Author(s) : Sanchez-Hernandez JC , Notario Del Pino J , Dominguez J
Ref : Ecotoxicology & Environmental Safety , 122 :EES15582 , 2015
Abstract : Soil enzyme activities are attracting widespread interest due to its potential use in contaminant breakdown, and as indicators of soil deterioration. However, given the multiple environmental and methodological factors affecting their activity levels, assessment of soil pollution using these biochemical endpoints is still complex. Taking advantage of the well-known stimulatory effect of earthworms on soil microbes, and their associated enzyme activities, we explored some toxicological features of carboxylesterases (CbEs) in soils inoculated with Lumbricus terrestris. A microplate-scale spectrophotometric assay using soil-water suspensions was first optimized, in which kinetic assay parameters (Km, Vmax, dilution of soil homogenate, and duration of soil homogenization) were established for further CbE determinations. Optimal conditions included a soil-to-water ratio of 1:50 (w/v), 30-min of shaking, and 2.5mM of substrate concentration. As expected, CbE activity increased significantly in soils treated with L. terrestris. This bioturbed soil was used for exploring the role of CbE activity as a bioscavenger for organophosphorus (OP) pesticides. Soil treated with two formulations of chlorpyrifos revealed that CbE activity was a significant molecular sink for this pesticide, reducing its impact on soil microbial activity as shown by the unchanged dehydrogenase activity. Dose-dependent curves were adjusted to an exponential kinetic model, and the median ecological dose (ED50) for both pesticide formulations was calculated. ED50 values decreased as the time of pesticide exposure increased (14d-ED50s=20.4-26.7mgkg-1, and 28d-ED50s=1.8-2.3mgkg-1), which suggested that chlorpyrifos was progressively transformed into its highly toxic metabolite chlorpyrifos-oxon, but simultaneously was inactivated by CbEs. These results were confirmed by in vitro assays that showed chlorpyrifos-oxon was a more potent CbE inhibitor (IC50=35.5-4.67nM) than chlorpyrifos (0.41-0.84muM). The results showed that earthworm-induced CbE activity is an efficient bioscavengers for OP pesticides, acting as a soil safeguarding system. Moreover, the simple dose-response curves against OP exposure suggest that this enzyme - combined with other enzyme activities (e.g., dehydrogenase) - may be a suitable biomarker of pesticide exposure.
ESTHER : Sanchez-Hernandez_2015_Ecotoxicol.Environ.Saf_122_EES15582
PubMedSearch : Sanchez-Hernandez_2015_Ecotoxicol.Environ.Saf_122_EES15582
PubMedID: 26300118

Title : Pulsed electromagnetic fields induce peripheral nerve regeneration and endplate enzymatic changes - De Pedro_2005_Bioelectromagnetics_26_20
Author(s) : De Pedro JA , Perez-Caballer AJ , Dominguez J , Collia F , Blanco J , Salvado M
Ref : Bioelectromagnetics , 26 :20 , 2005
Abstract : An experimental study was carried out in rats with the purpose of demonstrating the capacity of pulsed electromagnetic fields (PEMFs) to stimulate regeneration of the peripheral nervous system (PNS). Wistar and Brown Norway (BN) rats were used. Direct sciatic nerve anastomoses were performed after section or allograft interposition. Treatment groups then received 4 weeks of PEMFs. Control groups received no stimulation. The evaluation of the results was carried out by quantitative morphometric analysis, demonstrating a statistically significant increase in regeneration indices (P < 0.05) in the stimulated groups (9000 +/- 5000 and 4000 +/- 6000) compared to the non-stimulated groups (2000 +/- 4000 and 700 +/- 200). An increase of NAD specific isocitrate dehydrogenase (IDH) activity was found along with an increase in the activity of acetyl cholinesterase at the motor plate. The present study might lead to the search for new alternatives in the stimulation of axonal regenerative processes in the PNS and other possible clinical applications.
ESTHER : De Pedro_2005_Bioelectromagnetics_26_20
PubMedSearch : De Pedro_2005_Bioelectromagnetics_26_20
PubMedID: 15605398

Title : Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit - Gil-Bea_2005_Neurosci.Lett_375_37
Author(s) : Gil-Bea FJ , Garcia-Alloza M , Dominguez J , Marcos B , Ramirez MJ
Ref : Neuroscience Letters , 375 :37 , 2005
Abstract : Cognitive deficits in neuropsychiatric disorders, such as Alzheimer's disease (AD), have been closely related to cholinergic deficits. We have compared different markers of cholinergic function to assess the best biomarker of cognitive deficits associated to cholinergic hypoactivity. In post-mortem frontal cortex from AD patients, acetylcholine (ACh) levels, cholinacetyltransferase (ChAT) and acetylcholinesterase (AChE) activity were all reduced compared to controls. Both ChAT and AChE activity showed a significant correlation with cognitive deficits. In the frontal cortex of rats with a selective cholinergic lesion, all cholinergic parameters measured (ACh levels, ChAT and AChE activities, "in vitro" and "in vivo" basal ACh release) were significantly reduced. AChE activity was associated to ChAT activity, and even more, to "in vivo" and "in vitro" basal ACh release. Quantification of AChE activity is performed by an easy and cheap method and therefore, these results suggest that determination of AChE activity may be used as an effective first step method to evaluate cholinergic deficits.
ESTHER : Gil-Bea_2005_Neurosci.Lett_375_37
PubMedSearch : Gil-Bea_2005_Neurosci.Lett_375_37
PubMedID: 15664119